The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two-and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment.
Hepatitis B virus (HBV) infection, the leading cause of liver failure, is a global health problem with more than 400 million people infected worldwide up to now (1) . HBV-related liver diseases cause over 1 million deaths every year (2) . Active HBV infection can be indicated by hepatitis B surface antigen and HBV DNA in serum (3) . The pathogenesis of liver failure caused by HBV infection is as follows. HBV replication leads to a primary injury of liver cells and the host's immune cells such as cytotoxic T lymphocytes, and HBV replication causes a secondary lesion to the HBV-infected hepatocytes during viral clearance (4) . Following this, patients may suffer from another two attacks of ischemic-hypoxic injury and endotoxemia (5) .
There is no standard therapy for liver failure. Although liver transplantation is considered a life-saving treatment, its clinical use is hindered by the difficulty of finding suitable donors (6) . Although an artificial and bioartificial liver support system is available for the treatment of liver failure, its efficacy and safety remain to be improved (7) . In the past JIAN years, efficacy of nucleoside analogues, such as lamivudine, entecavir, telbivudine and tenofovir, for HBV-related liver failure has been reported. Nucleoside analogues are antiviral drugs that prevent the progression of liver failure by reducing HBV DNA replication through suppression of HBV-polymerase activity (8) . There have been meta-analyses of the effects of nucleoside analogues for HBV-related liver failure treatment (9) (10) (11) . Some of them compare the outcomes of two kinds of nucleoside analogues while the others analyze the efficacy of nucleoside analogue treatment in comparison with the non-nucleoside analogue (non-NA) treatment (10, 11) . However, no conclusion on which nucleoside analogue is the most satisfactory drug for the treatment of HBV-related liver failure has not been reached yet. Therefore, a comprehensive comparison of lamivudine, entecavir, telbivudine and tenofovir efficacy for the HBV-related liver failure treatment is essential.
To identify the optimal therapy, a Bayesian network meta-analysis was conducted. Articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for the HBV-related liver failure treatment were reviewed to evaluate the outcomes, including one-month to three-month survival rates, HBV DNA (log IU mL -1 indicates virological characteristics), model of the end-stage liver disease (MELD) score (consists of three objective parameters, TBIL, Cr and INR, which indicate the severity of the liver condition) and mortality.
DATA SOURCES

Literature search strategy
Network meta-analysis was performed following the guidelines of PRISMA-NMA (12) . Relevant studies were obtained by searching electronic databases up to December 2016, including Pubmed and Embase. Keywords used for literature search were as follows: (hepatitis B or HBV) and (hepatic failure or liver failure or hepatargia) and (nucleoside analog* or nucleotide analog* or nucleoside analogue or lamivudine or LAM or entecavir or ETV or telbivudine or LdT or tenofovir disoproxil fumarate or TDF or adefovir). Language was restricted to English. In addition, the lists of retrieved articles were reviewed to identify additional literature.
Data extraction and quality assessment
Data extraction was performed by two investigators independently. Data extracted from each retrieved article were as follows: the first author's name, publication year, location, study period, study type, follow-up time, number of subjects, demographic data characteristics including gender, age, etc., and outcomes of indicators. Quality assessment of randomized controlled trials (RCTs) was conducted using the Cochrane risk of bias tool recommended in the Cochrane handbook. Methodological quality of cohort studies was analyzed according to the Newcastle-Ottawa Scale (NOS, G. A. Wells et al., University of Ottawa, Ontario, Canada). Any discrepancy during data extraction and quality assessment was solved through discussion with a third person. ) is a non-programming software used for prior assessment and implementation based on the Bayesian framework using the Markov chain Monte Carlo (MCMC) (13) . The network meta-analysis was performed by ADDIS software. Parameter settings of ADDIS software were as follows: the number of chains: 4, tuning iterations: 20000, simulation iterations: 50000, thinning interval: 10, inference samples: 10000, variance scaling factor: 2.5, and odds risk (OR) with 95 % confidence interval (CI) or mean difference (MD) with 95 % CI were used to estimate the data. In this study, all models were random effect models. Node-splitting analysis was used to evaluate inconsistency. When p-value was > 0.05, a consistency model was used; otherwise, an inconsistency model was used. Convergences of models were estimated by the Brooks-Gelman-Rubin method via checking the potential scale reduction factor (PSRF) (14) . The PSRF close to 1 indicates good convergence of the models and, in general, PSRF less than 1.2 is acceptable.
RESEARCH OUTCOMES
Characteristics of available studies
The flow chart of study selection and literature search is shown in Fig. 1 . After comprehensive search of the Pubmed and Embase databases, a total of 821 studies were identified. MELD -model for end-stage liver disease, NA -not applicable, non-NAs -non-nucleoside analogues, RCT -randomized controlled trial.
After a series of selections and searches, 12 articles were included in our meta-analysis (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The total number of hepatic failure patients was 1660, among which 563 patients were treated with lamivudine, 520 patients were treated with enticavir, 105 patients were treated with telbivudine, 14 patients were treated with tenofovir and 458 patients were treated with non-nucleoside analogues (non-NAs). The main characteristics of eligible studies are given in Table I . Quality assessment revealed that the quality of each study was high: NOS scores of the cohort study ranged from 6 to 9 and most of the categories were of low risk in the RCT study.
Network meta-analyses of survival rates
One-month survival rate, two-month survival rate and three-month survival rate were analyzed using ADDIS software. Inconsistency was estimated by the node-splitting analysis; p > 0.05 indicated consistency (Table II) . The PSRFs ranged from 1.00 to 1.02, suggesting that convergence of the models was complete, the effects of iteration were very good and the results were stable. Therefore, consistency models were chosen. As shown in Table III and Fig. 2a , the one-month survival rate in the telbivudine group patients was 
Network meta-analysis of HBV DNA
The p < 0.05 suggested that there was significant inconsistency (Table II) . The PSRFs ranged from 1.00 to 1.03, indicating that model convergences were complete. Hence, an inconsistency model was used. Our results from Table III show that the concentration of HBV DNA in the enticavir group was the lowest and there was a significant difference compared to the non-NAs group (MD = -2.66, 95 % CI: -5.19 to -0.16), but there were no significant differences between the enticavir group and the other two nucleoside analogue groups, including the lamivudine group (MD: -0.33; 95 % CI: -1.91 to 1.25) and telbivudine group (MD: -0.25; 95 % CI: -4.73 to 4.08). 
Network meta-analysis of MELD score
Inconsistency assessment for the MELD score revealed that all p-values were greater than 0.05 (Table II) and PSRFs ranged from 1.00 to 1.02. Hence, a consistency model was chosen. As shown in Table III and Fig. 2d , the tenofovir group had the lowest MELD score. There was also a significant difference between the tenofovir group and the non-NAs group (MD: -7.85, 95 % CI: -13.27 to -2.20) while the differences between the tenofovir group and the other nucleoside analogues groups, including enticavir group (MD: 
Network meta-analysis of mortality
p-Values between the lamivudine group and the non-NAs group and between the enticavir group and the non-NAs group were found to be less than 0.05 (Table II) , indicating that the inconsistency was significant. The PSRFs ranged from 1.00 to 1.03 and, as a result, an inconsistency model was used. Mortality of the tenofovir group was found to be the lowest (Table III) 
DISCUSSION AND LIMITATIONS
It is reported that the three-month survival rate of ACLF patients receiving tenofovir treatment was significantly higher than that of the placebo group, and the MELD score and HBV DNA level were significantly reduced in the tenofovir group compared to the placebo group (22) . In addition, tenofovir inhibited the viral DNA replication of lamivudine-resistant HBV in patients infected with HBV or patients co-infected with HBV and HIV (27) . Besides, Ceylan et al. (28) reported that the virological response was better in chronic HBV infected patients treated with tenofovir than in patients treated with entecavir, while the side effects were not significantly different between the two nucleoside analogues. Furthermore, Lee et al. (29) revealed that in patients infected with lamivudine-resistant HBV, tenofovir monotherapy was as effective as the combination of tenofovir with lamivudine or telbivudine. It is also reported that treatments with both tenofovir and telbivudine were effective and the safety of the two nucleoside analogues was acceptable, but the estimated glomerular filtration rate (eGFR) was deteriorated in the tenofovir group while the telbivudine group showed improvement in eGFR (30) . In addition, tenofovir had superior antiviral efficacy in patients with chronic hepatitis B compared to adefovir, another nucleoside analogue with a similar safety profile (31) . Also, tenofovir was reported to have successfully rescued a hepatic decompensation patient infected with an adefovir resistant HBV mutant (32) . The results of these studies demonstrate that the effects of tenofovir for treating HBV infection are better than or as good as other nucleoside analogues, including lamivudine, entecavir, telbivudine, tenofovir and adefovir, while their safety is acceptable. In line with previous studies, our present study showed that tenofovir treatment had the highest two-month and three-month survival rates, indicating that the patients treated with tenofovir had a higher short-term survival rate compared to patients treated with other nucleoside analogues despite the differences not being significant. Besides, patients treated with tenofovir showed the lowest MELD score and mortality, suggesting that patients might have a better prognosis after being treated with tenofovir. Such results indicated that tenofovir was more effective than other nucleoside analogues and non-NAs in the treatment of patients with HBV-related liver failure.
To the best of our knowledge, this study was the first network meta-analysis comparing the efficacy of four nucleoside analogues, including lamivudine, entecavir, telbivudine and tenofovir, and non-NAs treatment, for the treatment of HBV-related liver failure. Major limitations of our study were as follows. First, due to incomplete data, no subgroup analysis was conducted. Second, not all drugs formed an closed loop and the number of included studies was limited, which might have resulted in exaggerated efficacy. Third, this study was unable to include all nucleoside analogues such as adefovir because of the lack of suitable studies. Fourth, out of 12 included studies, ten were conducted in China, and the other 2 studies were also from Asian countries, which might be associated with race and treatments. Hence, further tracking of related studies is needed. Fifth, only 2 RCT studies were included in the present study, the majority of studies were cohort studies, the level of evidence of which was not as good as RCT. Further studies could not be performed because of fewer RCT studies.
CONCLUSIONS
In the present study, to compare the therapeutic effect of four nucleoside analogues, we conducted a network meta-analysis based on the Bayesian framework. Our results showed that the tenofovir treatment had the highest two-month and three-month survival rates, the lowest MELD score and mortality. In conclusion, to compare the efficacy of NAs in the treatment of HBV-related liver failure, our results suggested that tenofovir might be better therapy for the treatment of HBV-related liver failure than other nucleoside analogues and non-NAs. The results of our meta-analysis may be useful as a guide for the clinical treatment of HBV-related liver failure.
